| Literature DB >> 29666504 |
Yuan Zhang1,2, Wen Zou3, Lemeng Ren4, Yinghui Zhang5, Zhaohui Sun6, Huandi Liu7, Qian Liu8, Chunfeng Si7, Hongying Jia9.
Abstract
The Chinese government has issued the policy of promulgating the clinical use of antibacterial drugs since 2011. Prophylactic antibiotic use is a challenging problem among young children with intussusception after successful air enema reduction. There were limited data regarding the clinical value of prophylactic antibiotics for intussusception with low-risk infections. A retrospective non-randomized comparative study was conducted among 188 young children with intussusception after successful air enema reduction between January 1, 2011 and December 30, 2013. Among these children, 51 received prophylactic antibiotics and 137 did not receive antibiotics. Our results showed that there were no significant differences in age, gender, weight, admission period, reduction interval, axillary temperature, leukocytes, neutrophils, lymphocytes, monocytes, mesenteric lymph nodes and complications between groups (P > 0.05). The national policy had significantly improved clinical use of antibiotic for young children with low-risk intussusception (OR < 0.001, P < 0.001). Inpatients days were longer for children used antibiotics than those who did not (median, 27.0 hours vs 21.0 hours, P = 0.003). Prophylactic antibiotics appeared to be of little value after the successful air enema reduction of intussusception in young children with low-risk infection. Policy intervention is effective for antibiotic use in China.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29666504 PMCID: PMC5904166 DOI: 10.1038/s41598-018-24415-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Procedure of recruiting young children for antibiotic use analysis.
Comparison of physiological characteristics among young children with intussusception before air enema reduction (mean ± SD, n, %).
| Prophylactic antibiotics (n = 51) | No antibiotics (n = 137) |
|
| ||
|---|---|---|---|---|---|
| Age (months) | 18.9 ± 10.2 | 19.7 ± 11.4 | 0.422 | 0.673 | |
| Weight (kg) | 11.6 ± 2.8 | 12.0 ± 2.9 | 0.971 | 0.333 | |
| Length of mass (mm) | 47.5 ± 9.4 | 42.2 ± 12.4 | −3.118 | 0.007 | |
| Diameter of mass (mm) | 25.9 ± 5.1 | 23.8 ± 5.8 | −2.254 | 0.025 | |
| Gender | male | 32 (62.8) | 91 (66.4) | 0.222 | 0.637 |
| female | 19 (37.3) | 46(33.6) | |||
| Admission period | 0:00–7:59 | 7 (13.7) | 13 (9.5) | 0.879 | 0.644 |
| 8:00–16:59 | 25 (49.0) | 75 (54.7) | |||
| 17:00–23:59 | 19 (37.3) | 49 (35.8) | |||
| Temperature (°C) | normal | 40 (78.4) | 99 (72.3) | 0.734 | 0.392 |
| >37.4 | 11 (21.6) | 38 (27.7) | |||
| Leukocytes (109/L) | normal | 34 (66.7) | 96 (70.1) | 0.202 | 0.653 |
| >9.5 | 17 (33.3) | 41 (29.9) | |||
| Neutrophils (109/L) | normal | 44 (86.3) | 102 (74.5) | 2.994 | 0.084 |
| >6.3 | 7 (13.7) | 35 (25.6) | |||
| Lymphocytes (109/L) | normal | 23 (45.1) | 68 (49.6) | 0.306 | 0.580 |
| >3.2 | 28 (54.9) | 69 (50.4) | |||
| Monocytes (109/L) | normal | 27 (52.9) | 56 (40.9) | 2.194 | 0.139 |
| >0.6 | 24 (47.1) | 81 (59.1) | |||
| Mesenteric lymph | normal | 23 (45.1) | 64 (46.7) | 1.418 | 0.492 |
| hyperplasia | 27 (52.9) | 65 (47.5) | |||
| lymphadenitis | 1 (2.1) | 8 (5.8) | |||
| Complications | none | 51 (100.0) | 131 (95.6) | 2.307 | 0.129 |
| have | 0 (0.0) | 6 (4.4) | |||
Figure 2The change in the proportion of prophylactic antibiotics in the preintervention and postintervention periods.
Logistic regression analysis of antibiotic use among young children with intussusception.
| Estimate | SE | χ2 | OR |
| |
|---|---|---|---|---|---|
| Length of mass (mm) | 0.088 | 0.059 | 2.206 | 1.092 | 0.137 |
| Diameter of mass (mm) | 0.039 | 0.102 | 0.148 | 1.040 | 0.700 |
| Policy intervention | −8.139 | 1.381 | 34.715 | <0.001 | < |
Comparisons of costs (CNY) among children with intussusception based on antibiotic administration (median, inter-quartile range, n, %).
| Prophylactic antibiotics (n = 51) | No antibiotics (n = 137) | Z |
| |
|---|---|---|---|---|
| Short-term efficacy (cured) | 51 (100.0) | 137 (100.0) | 0.000 | 1.000 |
| Inpatients days (hours) | 27.0 (20.5–37.5) | 21.0 (16.3–28.8) | −2.955 |
|
| Total inpatient cost | 1201.7 (960.1, 1573.3) | 1120.6 (982.8, 1428.3) | −0.885 | 0.376 |
| Imaging cost | 330.0 (330.0, 330.0) | 330.0 (330.0, 330.0) | −1.815 | 0.070 |
| Laboratory cost | 42.0 (20.0, 45.0) | 25.0 (0.0, 50.0) | −0.244 | 0.807 |
| Procedure cost | 232.0 (219.0, 245.0) | 220.0 (215.0, 227.0) | −4.278 | < |
| Antibiotics cost | 205.0 (140.0, 333.0) | 0.0 (0.0, 0.0) | −13.451 | < |
| Bed cost | 50.0 (40.0, 80.0) | 50.0 (40.0, 60.0) | −0.003 | 0.998 |
| Nursing cost | 9.0 (9.0, 18.0) | 9.0 (9.0, 18.0) | −0.933 | 0.351 |
| Materials cost | 160.7 (139.4, 194.9) | 132.3 (96.9, 152.9) | −4.981 | < |